Compare Bristol-Myers Squibb Co (BMY) vs Goldman Sachs Group Inc (GS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Goldman Sachs Group Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.71 (market cap $129.94B), while Goldman Sachs Group Inc trades at $1,038 (market cap $301.19B). The key difference: Goldman Sachs Group Inc is far larger — about 2.3× Bristol-Myers Squibb Co's market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | GS | |
|---|---|---|
Market Cap | $129.94B | $301.19B |
Sector | Health | Financials |
52-Week High | $65.89 | $1.15K |
52-Week Low | $42.60 | $715.95 |
Enterprise Value | $163.92B | — |
Dividend Yield | 3.96% | 1.93% |
Volume | — | 2,592,735 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
Goldman Sachs (GS) trades at $1,034.51, down 0.49% on the day, with a neutral technical signal and strong fundamental performance. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $20.98 surpassing the $14.47 estimate. Revenue growth is robust, rising to $58.28 billion in 2025, and net income margin expanded to 31.68%. The company is positioned to benefit from a surge in investment banking activity, including leading high-profile IPOs like Anthropic.
The outlook is positive given earnings momentum and strategic positioning in key deals, but risks include volatile cash flows and high leverage. Analyst consensus is a Buy with a $1,160 price target, implying potential upside. Investors should weigh strong profitability against macroeconomic sensitivity and balance sheet pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Goldman Sachs Group Inc
The Goldman Sachs Group, Inc., a bank holding company, is a global investment banking and securities firm specializing in investment banking, trading and principal investments, asset management and securities services. The Company provides services to corporations, financial institutions, governments, and high-net worth individuals.
Read more on GS →
